Weekly Guideline - 2015 AHA "Identification of Obesity and Cardiovascular Risk in Ethnically and Racially Diverse Populations"

"Identification of Obesity and Cardiovascular Risk in Ethnically and Racially Diverse Populations"

http://circ.ahajournals.org/content/132/5/457

CIRC - "Risk of Cardiomyopathy in Younger Persons With a Family History of Death from Cardiomyopathy"

"Risk of Cardiomyopathy in Younger Persons With a Family History of Death from Cardiomyopathy"

"Conclusions—A family history of premature cardiomyopathy death was associated with an increase in risk of cardiomyopathy ranging from 6- to 400-fold, depending on age, kinship, gender and number of affected family members. Our general population-based results support recommendations for presymptomatic screening of relatives of cardiomyopathy patients."
http://circ.ahajournals.org/content/132/11/1013.abstract

BMJ - "Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial"

"Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial"

"Conclusions
There is no evidence that bivalent HPV vaccination affects the risk of miscarriage for pregnancies conceived less than 90 days from vaccination. The increased risk estimate for miscarriages in a subgroup of pregnancies conceived any time after vaccination may be an artifact of a thorough set of sensitivity analyses, but since a genuine association cannot totally be ruled out, this signal should nevertheless be explored further in existing and future studies."

http://www.bmj.com/content/351/bmj.h4358 

NEJM - "Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes"

"Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes"

"RESULTS

The rate of major adverse cardiovascular events was not significantly lower with bivalirudin than with heparin (10.3% and 10.9%, respectively; relative risk, 0.94; 95% confidence interval [CI], 0.81 to 1.09; P=0.44), nor was the rate of net adverse clinical events (11.2% and 12.4%, respectively; relative risk, 0.89; 95% CI, 0.78 to 1.03; P=0.12). Post-PCI bivalirudin infusion, as compared with no infusion, did not significantly decrease the rate of urgent target-vessel revascularization, definite stent thrombosis, or net adverse clinical events (11.0% and 11.9%, respectively; relative risk, 0.91; 95% CI, 0.74 to 1.11; P=0.34)."

http://www.nejm.org/doi/full/10.1056/NEJMoa1507854

JAMA - "Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy"

"Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy"

"Conclusions and Relevance  Among patients with diabetic nephropathy, most receiving an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, the addition of finerenone compared with placebo resulted in improvement in the urinary albumin-creatinine ratio. Further trials are needed to compare finerenone with other active medications."

http://jama.jamanetwork.com/article.aspx?articleid=2432163

Weekly Guideline - 2015 AHA / ADA "Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence"

"Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence"

http://circ.ahajournals.org/content/132/8/691

CIRC - "Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines"

"Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines"

"Conclusions—In this generally low-risk population sample, a large proportion of ASCVD events occurred among adults with a 10-year cPCE risk <7.5%. We found that the coronary artery calcium score, high-sensitivity C-reactive protein, family history of ASCVD, and ankle-brachial index recommendations by the American College of Cardiology/American Heart Association cholesterol guidelines (Class IIB) identify small subgroups of asymptomatic population with a 10-year cPCE risk <7.5% but with observed ASCVD event rates >7.5% who may warrant statin therapy considerations."

http://circ.ahajournals.org/content/132/10/916.full